Log In
CQMS
Make a Donation
Log In
Donate
DONATE OR FUNDRAISE
Donate
Read Roland's story about participating in a prostate cancer trial
2026 Clinical Research Education Workshop (CREW) - Virtual attendance now available
Notice of AGM of the Trans Tasman Radiation Oncology Group .
First participant recruited for new lung cancer trial

TROG 92.01 – PCNSL (Phase II)

Completed
Lymphoma

A Phase II Study of Intravenous Methotrexate and Cranial Irradiation in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)
Prev Post

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

Next Post

TROG 91.01 – Head & Neck – Accelerated RT

Related Post

26 March, 2026

TROG welcomes new Board members and President-Elect

LATEST NEWS: 26 March 2026 We are delighted to

26 March, 2026

TROG’S 38th ASM puts focus on driving innovative trials

LATEST NEWS: 26 March 2026 TROG’s 2026 Annual Scientific